Patients not on treatment or on other antihyperglycemic agents entered a run-in treatment period of up to 12 weeks duration with metformin HCl monotherapy (dose of 1500 mg per day) which included washout of medications other than metformin, if applicable
Pharmacy Benefit Managers Will Adapt PBMs are beginning to offer GLP-1-specific solutions, such as value-based pricing or outcome guarantees, which could ease the cost burden
Tirzepatide reduces input more efficiently
Underexplored peptide systems frequently encounter attrition after biological validation but before pharmacologic optimization, whereas GLP-1 progressed through these stages following the introduction of enabling technologies
[DOI] [PubMed] [Google Scholar] Garnier R, Boudignat O, Fournier PE
For active adults, though, the same mechanisms can create a different challenge